SCHEMBL3532037

SCHEMBL3532037

CC(C)NS(=O)(=O)CCc1ccc(N)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RECQL P46063 1/20 0.53
GFER P55789 1/20 0.43
NPSR1 Q6W5P4 1/20 0.42
CA12 O43570 1/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
CA6 P23280 1/20 0.40
CA5A P35218 1/20 0.40
CA7 P43166 1/20 0.40
CA9 Q16790 1/20 0.40
CA14 Q9ULX7 1/20 0.40
CA5B Q9Y2D0 1/20 0.40
MMP8 P22894 3/20 0.39
MMP12 P39900 3/20 0.39
MMP13 P45452 3/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
MAOB P27338 3/20 0.38
MAOA P21397 2/20 0.38
PRMT1 Q99873 1/20 0.37
GAA P10253 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2993430 0.82 ALDH1A1 (0.44) RECQLGFERNPSR1CA12CA1
SCHEMBL10879503 0.82 IDO1 (0.54) NPSR1CA2MMP8MMP12MMP13
SCHEMBL1275321 0.80 RECQL (0.58) RECQLGFERCA12CA1CA2
Hydrochloric Acid SCHEMBL4731092 0.79 RECQL (0.61) RECQLGFERCA12CA1CA2
SCHEMBL3082582 0.76 RECQL (0.53) RECQLGFERCA12CA1CA2
SCHEMBL2044233 0.75 RECQL (0.67) RECQLGFERCA12CA1CA2
SCHEMBL4573196 0.75 DHFR (0.53) RECQLGFERCA12CA1CA2
SCHEMBL3532040 0.75 CA2 (0.56) RECQLGFERCA12CA1CA2
SCHEMBL3090369 0.74 RECQL (0.55) RECQLGFERCA12CA1CA2
SCHEMBL11281060 0.73 RECQL (0.69) RECQLGFERCA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7642270-B2 5-oxo-5,8-dihydro-pyrido-pyrimidine as inhibitors of c-fms kinase JANSSEN PHARMACEUTICA N.V. (BE) 2010-01-05 US disclosed
EP-1937681-A1 5-OXO-5,8-DIHYDRO-PYRIDO-PYRIMIDINES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA N.V. (BE) 2008-07-02 EP disclosed
WO-2007033232-A1 5-OXO-5,8-DIHYDRO-PYRIDO-PYRIMIDINES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA, N.V. (BE) 2007-03-22 WO disclosed
WO-2007033232-A1 5-OXO-5,8-DIHYDRO-PYRIDO-PYRIMIDINES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA, N.V. (BE) 2007-03-22 WO disclosed
US-20070060577-A1 5-Oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase JANSSEN PHARMACEUTICA N.V. (BE) 2007-03-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070060577-A1 5-Oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase FLT3, FES, FGR RECQL 1301/4885GFER 2722/4885NPSR1 1756/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.